SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing intense investor backlash following the abrupt cancellation of a major contract with Marvell, which was triggered by the CFO's alleged violation of a confidentiality agreement. The community is sharply divided between those calling for immediate leadership changes to restore credibility and those attempting to buy the dip, citing the company's underlying photonics technology as a reason for long-term optimism.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as it hits new record highs, fueled by intense institutional demand and optimistic sentiment surrounding its dominance in the AI infrastructure cycle. Investors are actively debating the sustainability of its multi-trillion-dollar valuation, with bulls pointing to fundamental growth while skeptics monitor for potential signs of overheating.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending amid investor excitement over potential merger activity and a significant acquisition plan involving European Lithium, which investors believe could consolidate control of its Greenland-based Tanbreez project. The community is focused on the strategic importance of the company's rare earth assets for U.S. and European defense supply chains, fueling a debate between long-term bulls anticipating a supply-side squeeze and short-term traders reacting to volatility and corporate structure updates.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is trending as a momentum-driven play, with investors closely watching for signs of a short squeeze amid high volatility and active sentiment regarding potential price swings. The community is heavily focused on the stock's thin float and the influence of speculative trading patterns, frequently comparing its aggressive moves to previous market runners.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is currently trending as a prominent infrastructure play in the AI hardware sector, with investors closely watching for earnings-driven volatility after the company's recent strategic collaborations, such as the AMD Helios platform partnership. The community is actively debating the company's valuation relative to its hyperscaler demand, with many focused on whether this quarter will trigger a major breakout or another round of consolidation as it navigates significant institutional interest.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as investors react to a series of strategic acquisitions, including the purchase of tokens.com/ and plans to acquire F9 Brands, as the company pivots toward a comprehensive home services and retail ecosystem. While some in the community express optimism about the potential for a turnaround and synergy, others remain deeply skeptical, citing concerns over historical cash burn, dilution, and the sustainability of the company's new business model.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is experiencing intense volatility and volume-driven interest as investors monitor a tight effective float and speculate on potential buyout scenarios or strategic partnerships. The community remains deeply divided, with bullish participants pointing to recent institutional accumulation and clinical data, while others express skepticism regarding management's communication history and the potential for near-term equity dilution.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as the community debates its progress in the eVTOL sector, specifically highlighting its recent demonstration flights in New York City and its ongoing collaboration with Toyota for manufacturing scale. Investors are actively discussing the company's long-term potential versus execution risks, with some closely monitoring the technical price action and options activity as catalysts for the stock's next move.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently under intense scrutiny from the community following the release of Phase 3 results for its CRISPR-based HAE therapy, which met primary and secondary endpoints but has sparked debate over efficacy compared to existing oral alternatives. Investors are actively discussing the stock's high short interest, the potential for a short squeeze, and concerns over future dilution via the company's ATM facility, leaving sentiment sharply divided between those betting on a long-term breakthrough and those wary of clinical and commercial risks.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is under significant pressure following cautious financial guidance and uncertainty surrounding the transition away from its favorable reimbursement period for DefenCath. While the community remains divided between those viewing the current valuation as deeply discounted due to strong fundamentals and others frustrated by leadership's communication, investors are now closely watching for Phase 3 REZZAYO data and potential legislative breakthroughs to drive the next catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$WB
Share Price: $9.53

Contract Selected: Jul 17, 2026 $10 Calls

Buy Zone: $0.44 – $0.54
Target Zone: $0.74 – $0.90
Potential Upside: 60% ROI

Time to Expiration: 132 Days | Updates via https://fxcapta.com/stockinfo/

Every trade is a home run. Over 96% win rate on all trades for the past two years, over 1,000,000+ total trades. Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute financial advice. Trading involves risk, and past performance is not indicative of future results.

Fxcapta

fxcapta.com

StockTwits Web

WEIBO


Share Price: $9.53

Contract Selected: Jul 17, 2026 $10 Calls

Buy Zone: $0.44 – $0.54
Target Zone: $0.74 – $0.90
Potential Upside: 60% ROI

Time to Expiration: 132 Days | Updates via 